Health Condition 1: P228- Other respiratory distress of newborn
Conditions
Interventions
None listed
Sponsors
Manipal academy of higher education
Eligibility
Inclusion criteria
Inclusion criteria: Neonates prescribed with Amikacin Neonates whose blood samples were sent for routine investigations
Exclusion criteria
Exclusion criteria: Preterm neonates Neonates who are clinically unstable Neonates whose parents/guardians unable or unwilling to give consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Amikacin concentrations will be estimated from blood plsama 2. clinical and nonclinical factors influencing the amikacin kinetics in neonates will be studied 3. population pharmacokinetic model will be developed for amikacin in neoneates.Timepoint: 1.amikcin concentration will be estimated once in every 3 months 2. factors influencing amikacin kinetics will be started to analyze after 6 months 3. population pharmacokinetics model will be developed with in 36 months from the initiation of study | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To identify the co-variates affecting amikacin clearance in neonates.Timepoint: 1. covarite analysis will be started after 1 year | — |
Countries
India
Contacts
Public ContactMatcha Saikumar
Manipal college of pharmaceutical sciences
Outcome results
None listed